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Edited by Ned ManteiAbstract Astrocytes are generated from neuroepithelial cells
after neurons during brain development. However, the mecha-
nism of this sequential generation is not fully understood. Here,
we show that a particular cytosine residue in the promoter of the
gene encoding the immature astrocyte marker, S100b, becomes
demethylated, correlating with the time when the S100b expres-
sion commences at embryonic day (E) 14. In addition, astrocyte-
inducing cytokine, BMP2, increased histone acetylation around
the CpG site in neuroepithelial cells at E14 but not E11 when
S100b expressing astrocytes are absent. Furthermore, binding of
a methyl DNA binding protein, MeCP2, to the S100b gene
promoter in neuroepithelial cells was reduced at E14 compared
to E11. Thus, demethylation of speciﬁc CpG site is suggested to
be a critical determinant in regulating astrocyte diﬀerentiation in
the developing brain.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
Keywords: Neural stem cell; Astrocyte; Diﬀerentiation;
Development; DNA-methylation; Chromatin modiﬁcation1. Introduction
During the development of the central nervous system
(CNS), neurons and astrocytes are generated from common
precursor cells present in the neuroepithelium [1–3]. In the
mammalian CNS, neurons are generated primarily during the
embryonic period [4]. For example, in the mouse cerebral
cortex, neurogenesis commences around embryonic day 11
(E11), peaks at about E15, and ﬁnishes around birth [5,6].
While transient radial glia are present during the early stages
of development, macroglial production in the cortex is delayed
until mid-gestation and only occurs at low levels. While cor-
tical astrocytes are ﬁrst apparent at E16 and oligodendrocytes
around birth, the vast majority of both cell types are produced
during early neonatal development [7]. Although the separate
timing of neurogenesis and gliogenesis in the CNS has been
known for many years, the molecular mechanisms underlying
these processes remain largely unknown.
The speciﬁcation of cell lineages in the developing brain is
thought to be regulated by cell-external cues and cell-intrinsic* Corresponding author. Fax: +81-96-373-6610.
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doi:10.1016/j.febslet.2004.07.029programs. Cell-intrinsic programs include epigenetic modiﬁ-
cation such as chromatin remodeling and DNA methylation.
The cytosine in CpG dinucleotides of vertebrate genomes is
prone to modiﬁcation into 5-methylcytosine. This methylation
has been proposed as a means of transcriptional silencing [8,9].
The establishment of normally regulated DNA methylation is
essential for development [10], and abnormalities in regulating
DNA methylation are frequently associated with tumorigene-
sis [11] and cell aging [12].
Glial ﬁbrillary acidic protein (GFAP) and S100b are two
proteins often used to monitor astrocyte diﬀerentiation and
maturation. GFAP is considered the major component of glial
ﬁbrils and provides a viable index of astrocyte maturation,
while S100b is a soluble calcium-binding protein synthesized in
astrocytes and is known as a marker for immature astrocytes
[13]. During brain development, GFAP expression in neural
precursor cells is dependent on the activation of the tran-
scription factor, signal transducer and activator of transcrip-
tion 3 (STAT3) [14–16]. We have previously shown that a CpG
dinucleotide within a STAT3 binding element in the GFAP
promoter is highly methylated in E11.5 neuroepithelial cells,
post-mitotic neurons, and cells outside the nervous system, but
is demethylated in cells that exhibit STAT3-induced expression
of GFAP [17]. Based on this ﬁnding, we proposed that DNA
methylation is a pivotal event in regulating astrocyte diﬀer-
entiation during brain development. However, it remains
unclear whether this developmental stage-dependent demeth-
ylation is conﬁned to the GFAP gene promoter or is more
widespread in astrocyte-speciﬁc gene promoters in the fetal
brain. S100b is also known as an astrocytic marker and ex-
pressed during earlier stages of astrocytic development than
GFAP. We thus determined the methylation status of the
promoter for the S100b gene and proﬁled S100b gene expres-
sion during brain development.2. Materials and methods
2.1. Animals and cell preparation
Time-pregnant ICR mice were used to prepare neuroepithelial cells.
Mice were treated in accordance with the guidelines of Kumamoto
University Center for Animal Resources and Development. Neuro-
epithelial cells were prepared from telencephalons of E11.5 or E14.5
mice and cultured as described previously [18]. Brieﬂy, the telenceph-
alons were triturated in Hank’s balanced salt solution (HBSS) by mild
pipetting with a 1 ml pipette tip (Gilson). Dissociated cells were cul-
tured for four days in N2-supplemented Dulbecco’s Modiﬁed Eagle’s
Medium with F12 (Gibco) containing 10 ng/ml basic FGF (R&Dblished by Elsevier B.V. All rights reserved.
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poly-L-ornithine (Sigma) and ﬁbronectin (Life Technologies).2.2. Immunohistochemistry
Mouse embryos were ﬁxed in a 4% paraformaldehyde PBS solution
for 24 h, and serially submerged in PBS containing 10% and 20% su-
crose at 4 C for 24 h. The tissue was cut into 15 lm thick sections
using a cryostat. The sections were then stained with one of the fol-
lowing primary antibodies: mouse monoclonal antibodies speciﬁc for
S100b (Sigma) and polyclonal antibodies for MAP2 (Chemicon). The
following secondary antibodies were used: Cy3-conjugated anti-mouse
IgG (Jackson Laboratory), FITC-conjugated anti-rabbit (Chemicon).
Nuclei were stained with bisbenzimide H33258 ﬂuorochrome trihy-
drochloride (Nakaraitesque).
2.3. Immunocytochemistry
Cells were cultured on chamber slides (Nunc) either with or without
BMP2 (80 ng/ml, Yamanouchi Pharmaceutical) for 4 days, washed
with PBS, ﬁxed in 4% paraformaldehyde in PBS, and stained with one
of the following primary antibodies: anti-S100b (Sigma), anti-MAP2
(Chemicon). The following secondary antibodies were used: Cy3-
conjugated anti-mouse IgG (Jackson Laboratory), FITC-conjugated
anti-rabbit (Chemicon). Nuclei were stained with bisbenzimide H33258
ﬂuorochrome trihydrochloride (Nakaraitesque).2.4. RT-PCR
Total RNA was isolated from E11.5 or E14.5 neuroepithelial cells
cultured either with or without BMP2 (80 ng/ml) for 4 days. Reverse
transcriptions were performed using the RNA as a template and Su-
perscript II reverse transcriptase (GibcoBRL). PCRs were performed
using AmpliTaq Gold (Perkin–Elmer) with the following settings: 95
C for 9 min; 28 cycles at 94 C for 20 s, at 60 C for 20 s, at 72 C for
30 s; one cycle at 72 C for 5 min. The following primers were used:
S100b S, 50-AGAGGACTCCAGCAGCAAAGG-30; S100b AS, 50-
AGAGAGCTCAGCTCCTTCGAG.
2.5. Bisulﬁte sequencing
Sodium bisulﬁte treatment of genomic DNA was performed essen-
tially as described previously [19]. Brieﬂy, 5 lg of genomic DNA was
digested with SacI, denatured with 0.3 M NaOH at 37 C for 15 min
and incubated with 3.1 M sodium bisulﬁte and 0.5 mM hydroquinone
at 55 C for 16 h. The samples were puriﬁed using a desalting column
(Promega) in accordance with the manufacturer’s instructions and
eluted in 50 ll of H2O. 3 M NaOH (5.5 ll) was added and the samples
were incubated at 37 C for 15 min. The samples were ﬁrst neutralized
by the addition of 3 M ammonium acetate, then ethanol precipitated,
and dissolved in H2O. There are four CpG sites at positions )818,
)318, )207, and )64 relative to the transcription start site. Two DNA
fragments containing the former one and the latter three were ampli-
ﬁed, respectively, by PCR using the following sets of primers:
S100818MS, 50-GTTGTTGGGAATTGAATTTAGGATTTTTGG-30;
and S100818MAS, 50-ATCTTAAAACTCTCTCTCCCTACCC-
TAATC-30; and S100MS, 50-AAGTTGGTAGATAAGTAAGATG-
TTTAAGAG-30; and S100MAS, 50-ATCACCTTTACTACTAAAA-
TCCTCTCTAAC-30. The PCR products were cloned into pT7Blue
and 11–13 clones were randomly chosen from each of the three inde-
pendent PCRs and sequenced.
2.6. ChIP assay
Chromatin immunoprecipitation was performed as previously de-
scribed [20] with some minor modiﬁcations. Cells were exposed to
formaldehyde at a ﬁnal concentration of 1% added directly to the
tissue culture medium. Cells were centrifuged into a pellet after 10 min
of formaldehyde exposure, lysed in lysis buﬀer (1% SDS, 10 mM
EDTA, and 50 mM Tris–HCl, pH 8.1) containing protease and
phosphatase inhibitors [3 mM pAPMSF, 5 mg/ml aprotinine, 1 mg/ml
pepstatin A (Wako Chemicals), and 2 mM sodium orthovanadate] and
then incubated for 5 min on ice. Cell lysate was sonicated using a
microtip until the DNA fragments were 600–1000 base pairs in length.
Chromatin samples were diluted 1:10 with dilution buﬀer (0.01% SDS,
1.1% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris–HCl, pH 8.1, and
167 mM NaCl). 1% of the total volume was stored as input at )20 C
for later use. After the samples were pre-cleared with protein ASepharose beads (Amersham) containing 5 lg of sonicated phage
lambda DNA (Toyobo), immunoprecipitation was performed over-
night at 4 C with 1 lg of the antibody for either acetylated H3, H4 or
MeCP2 (Upstate Biotechnology). Immune complexes were collected
by protein A–Sepharose beads and washed with the following buﬀers:
low salt buﬀer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
Tris–HCl, pH 8.1, and 150 mM NaCl), high salt buﬀer (0.1% SDS, 1%
Triton X-100, 2 mM EDTA, 20 mM Tris–HCl, pH 8.1, and 500 mM
NaCl), LiCl buﬀer (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM
EDTA, and 10 mM Tris–HCl, pH 8.1) and TE buﬀer (10 mM Tris–
HCl and 1 mM EDTA, pH 8.0). Immune complexes were disrupted
with elution buﬀer (1% SDS and 50 mM NaHCO3) and the covalent
links between the immunoprecipitates and input chromatin were re-
versed by incubation with 300 mM NaCl at 65 C for 4 h. DNA was
further incubated with proteinase K, puriﬁed by phenol extraction,
and then ethanol-precipitated. DNA pellets were dissolved in 50 ll of
H2O and used as a template for PCR with the following set of primers.
Primers for the proximal promoter region of S100b gene were as fol-
lows: S100b promS, 50-TCCAGCACTCAGCATGAGAAG-30; S100b
promAS, 50-GTCAGTGGCTTTCTCACCTCC-30. Primers for the
)318 CpG site of the 100b promoter region were as follows:
S100b318S, 50-TTACTGCATGCTGGTCCCTG-30; S100b318AS, 50-
TAGAGTCAGCTTCTCTGCACC-30.3. Results
E11.5 or E14.5 mouse brains were ﬁxed and sections
stained for S100b and MAP2 proteins using immunohisto-
chemistry. S100b positive cells were detected in the subven-
tricular layer of the telencephalic cortex of E14.5 brains
(Fig. 1F), but not in the E11.5 brain, except for non-neural
tissues such as the brain meninges (Fig. 1B). MAP2 positive
cells were observed in the E11.5 preplate and E14.5 cortical
plate (Fig. 1A and E). No GFAP positive cells were observed
in these sections (data not shown). These results demonstrate
developmental stage dependent expression of S100b in the
fetal mouse brain.
We have previously shown that cells expressing S100b de-
velop from E14.5 mouse neuroepithelial cells after being cul-
tured with BMP2 for 2 days [21]. This suggests that BMP2
plays an important role in the development of S100b positive
cells from neural progenitors. To determine whether the re-
sponsiveness of neural progenitors to BMP2 is dependent on
the developmental stage, neuroepithelial cells were acutely
dissociated from E11.5 and E14.5 telencephalons and cultured
either with or without BMP2 for 4 days, and S100b and MAP2
proteins were labeled using immunohistochemistry and S100b
mRNA levels analyzed by RT-PCR.
As shown in Fig. 1J, S100b positive cells were induced by
BMP2 in a culture of acutely prepared E14.5 neuroepithelial
cells. S100b mRNA was also induced in the same culture
(Fig. 1M, lane 2). These results suggest that E14.5 neuroepi-
thelial cells express S100b following exposure to BMP2. In
contrast, no S100b immunoreactivity (Fig. 1L) and mRNA
were detected in E11.5 neuroepithelial cells cultured under the
same conditions (Fig. 1M, lane 4). These results indicate that
the responsiveness of neural progenitors to BMP2 is depen-
dent on the developmental stage. BMP receptor expression in
E11.5 neuroepithelial cells was conﬁrmed by RT-PCR
analysis (data not shown). The lack of S100b expression in
BMP2-stimulated E11.5 neuroepithelial cells may be due to
inactivation of the promoter region of the S100b gene. Using
bisulﬁte genomic sequencing analysis of acutely prepared or
4-day cultured neuroepithelial cells from either E11.5 or E14.5
telencephalons, we determined the methylation status of the
CpG sites of S100β
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Fig. 2. Speciﬁc CpG site in a promoter region of S100b is demethylated
during development. (A) CpG sites of the S100b gene promoter. Po-
tential methylation sites are shown by arrowheads. Numbering begins
with the transcription initiation site as +1. (B)–(D) The frequency of
methylation at each potential methylation site in the S100b promoter
gene was investigated using the bisulﬁte sequencing method. In this
assay, either freshly prepared or 4-day cultured neuroepithelial cells
from E11.5 or E14.5 mouse telencephalon were used.
Fig. 1. S100b expression and its responsiveness to BMP signal are
controlled by the developmental stage of the embryonic mouse brain.
(A)–(H) Double immunoﬂuorescence labeling of the proteins S100b (B
and F, red) and MAP2 (A and E, green) in the cortex of E11.5 or E14.5
mouse brains. MAP2 immunoreactivity was detected in the cortex of
both E11.5 and E14.5 mice. S100b immunoreactivity was only detected
in the intermediate zone of the cortex in E14.5 mice. Superimposed
views of A and B are shown in C, and superimposed views of E and F
are shown in G. DAPI staining indicates nuclei (D, H). V indicates the
ventricle. Bar¼ 50 lm. (I–L) Neuroepithelial cells prepared from E14.5
or E11.5 mouse telencephalons were cultured in the presence (J, L) or
absence (I, K) of BMP2 (80 ng/ml) for 4 days. Cells were stained with
antibodies for the astrocytic marker S100b (red) or the neuronal
marker MAP2 (green). No S100b-positive astrocytes were induced by
BMP2 in cultured E11.5 neuroepithelial cells (L), but were induced in
E14.5 neuroepithelial cells under the same conditions (J). Bar¼ 50 lm.
(M) Total RNA was extracted from E11.5 or E14.5 neuroepithelial
cells cultured in either the presence or absence of BMP2 (80 ng/ml) for
4 days, and was analyzed by RT-PCR using speciﬁc primer for S100b
and G3PDH.
186 M. Namihira et al. / FEBS Letters 572 (2004) 184–188four CpG dinucleotides present in an 860 base pair region of
the S100b gene promoter just upstream of the transcriptional
start site.
An 860 base pair-region within the mouse S100b promoter
was analyzed. There are four CpG sites at )818, )318, )207,
and )64 bases relative to the transcriptional start site
(Fig. 2A). Methylation in each cell group was determined by
sequencing 11 to 13 clones prepared from bisulﬁte-treated
genomic DNA. The experiments were performed three times
and the methylation frequency was calculated from the tripli-
cate cell preparation. As shown in Fig. 2B-E, all four of the
CpG sites were highly methylated in both acutely prepared and
4-day cultured E11.5 neuroepithelial cells, which express nei-
ther S100b in vivo nor S100b in vitro following exposure to
BMP2. It is notable that the methylation frequency at the )318
CpG site was signiﬁcantly reduced in E14.5 neuroepithelial
cells (Fig. 2C), which normally express S100b in vivo and
S100b in vitro after exposure to BMP2. In contrast, the
methylation frequency remained high at the other three CpG
sites. Hence, the methylation status of the CpG dinucleotide at
)318 correlates with S100b expression levels in neuroepithelialcells in vivo and S100b expression in cultured neuroepithelial
cells following stimulation by BMP2.
It is known that DNA methylation contributes to tran-
scriptional silencing of gene expression both by interfering
with the accessibility of transcription factors to their target
DNA and by recruiting methyl DNA binding domain-con-
taining proteins, which trigger the formation of inactive
chromatin structures [8]. Since we did not detect any of the
previously reported Smad-binding consensus sequences [22–
24] around the )318 CpG site in the S100b gene promoter,
methylation of this site in E11.5 neuroepithelial cells may
contribute to the formation of inactive chromatin structures
to inhibit transcriptional activation of the S100b gene. Among
the many proteins that bind to methylated DNA, MeCP2
characteristically binds to single, symmetrical methylated
CpG pairs in any sequence context and is linked to gene si-
lencing by recruiting histone deacetylases (HDACs) and co-
repressors, including mSin3A [25–27]. We thus investigated
whether MeCP2 participates in the regulation of S100b gene
repression.
ChIP was performed with E11.5- or E14.5-telencephalon-
derived neuroepithelial cells using an anti-MeCP2 antibody
and PCR primers to detect a DNA fragment spanning
)550 and )250 in the S100b gene promoter. As shown in Fig. 3A
and B, a signiﬁcant level of MeCP2 binding to the )318 CpG-
containing part of the S100b gene promoter was detected in
E11.5-telencephalon-derived cells, but was less apparent in
E14.5 cells. Downregulation of MeCP2 binding to this part of
the promoter in E14.5 cells appears to be in accordance with
the reduction in methylation frequency at the )318 CpG site.
This result suggests that the binding of MeCP2 to the methy-
lated )318 CpG site within the S100b gene promoter in E11.5
cells inactivates the gene.
Fig. 3. The inactive status of the chromatin structure of the S100b
promoter region in E11.5 neuroepithelial cells. (A and B) The abun-
dant binding of MeCP2 to the methylated )318 CpG site within the
S100b gene promoter region in E11.5 cells. (A) Results of an ChIP
assay performed with an antibody for MeCP2 in E11.5 or E14.5
neuroepithelial cells cultured with bFGF for 4 days. (B) Quantiﬁcation
of MeCP2 ChIP PCR results. The results were scanned and analyzed
by NIH Image. The signal intensity of each PCR band was measured
and normalized by the Input. The signal intensity of the band detected
in E11.5 cells was arbitrarily chosen as 1.0 and the MeCP2 binding
levels of each ChIP product were referred to as a multiple of that value.
(C and D) The chromatin structure of the S100b gene promoter in
E11.5 neuroepithelial cells was in the inactivated state for interference
with histone acetylation following stimulation with BMP2. (C) Chro-
matin immunoprecipitation assay performed using formaldehyde
cross-linked moderately sonicated chromatin from non-stimulated or
BMP2-stimulated (80 ng/ml) neuroepithelial cells. The DNA fragments
of the S100b promoter were immunoprecipitated using an antibody for
acetylated H3 and H4, and detected using PCR. (D) Quantiﬁcation of
the PCR products from chromatin preparation. The results of three
experiments were scanned and analyzed by NIH Image. The intensity
of each PCR band was measured and normalized by the Input. The
signal of the band detected in CTRL (open bar) of E11.5 or E14.5 cells
was arbitrarily chosen as 1.0 and the acetylation levels of the ChIP
products of BMP2 stimuli (closed bar) were referred to as a multiple of
that value.
M. Namihira et al. / FEBS Letters 572 (2004) 184–188 187To provide an indication of gene activation, we analyzed the
S100b gene promoter in E11.5 and E14.5 neuroepithelial cells
cultured for 4 days either with or without BMP2 for histone
acetylation. ChIP assays were performed using an antibody
speciﬁc to the acetylated histones H3 or H4, and a set of PCR
primers to detect the promoter fragment spanning )362 and
+11. BMP2 stimulation failed to induce acetylation of histonesH3 or H4 at the S100b gene promoter in E11.5-derived cells
(Fig. 3C and D, left-hand panels). This result suggests that in
E11.5 neuroepithelial cells, the chromatin structure of the
S100b gene promoter is in the inactivated state and cannot be
modiﬁed by BMP2 stimulation. In marked contrast, exposure
of E14.5-derived neuroepithelial cells to BMP2 for 4 days re-
sulted in a signiﬁcant increase in acetylation of histones H3,
and to a lesser extent, H4 in the S100b gene promoter com-
pared with non-treated cells (Fig. 3C and D, right-hand pan-
els). TGF-b proteins activate transcription through both a
physical and functional interaction of DNA binding Smads
with other sequence-speciﬁc transcription factors as well as the
coactivators CBP and p300. These coactivators possess (and
can also recruit proteins with) histone acetyltransferase activity
and acetylation of histones loosens the chromatin structure
facilitating gene transcription. Thus, these coactivators may
contribute to acetylation of histones in the S100b gene pro-
moter following BMP2 stimulation and lead to suﬃcient
transcriptional activation. The mechanism underlying BMP2-
induced acetylation of histones in the S100b gene promoter in
E14.5 neuroepithelial cells remains to be elucidated. Methyl-
ation of the )318 CpG site may keep a transcription factor
complex away from the S100b gene promoter in E11.5 neu-
roepithelial cells due to the inactive status of the chromatin
structure. Taken together, our results suggest that site-speciﬁc
DNA demethylation of the S100b gene promoter during em-
bryogenesis is required for S100b expression throughout brain
development.4. Discussion
In the mammalian brain, the majority of neurons are born
before glia cells develop [4]. A major question is therefore how
neural progenitors in the neuroepithelium show such develop-
mental stage dependent changes in the preference of cell-fate
determination, i.e., from neurogenesis in the earlier stages to
gliogenesis in later stages. In the present study, we show that
CpG dinucleotides in the promoter region of the gene for im-
mature astrocyte-speciﬁc protein S100b in E11.5 neuroepithe-
lial cells, which express S100b neither in vivo nor in vitro after
exposure to BMP2, are highly methylated and the chromatin
structure in the S100b promoter region is in the inactive state.
At the later developmental stage of E14.5, only one of the four
CpG dinucleotides examined is substantially demethylated, and
most likely facilitates BMP2-mediated induction of S100b ex-
pression. These results indicate that DNA demethylation of the
speciﬁc CpG dinucleotide in the S100b gene promoter coincides
with its expression in neural progenitors. Although we detected
acetylation of histones H3 and H4 in the S100b gene promoter
of 4-day cultured E11.5 cells not stimulated by BMP2, S100b
expression was not detected in the E11.5 cells. This result
suggests that negative regulators of astrocyte diﬀerentiation
such as Olig2 [28] or neurogenin1 [29] may also contribute to
the inhibition of astrocyte-speciﬁc S100b expression in E11.5
neuroepithelial cells through diﬀerent mechanisms from the
methylation of speciﬁc gene promoters.
In the present study, we show that S100b expression, which
is known to be an early marker for astrocyte diﬀerentiation, is
eﬃciently induced in E14.5 neuroepithelial cells by BMP2 and
that S100b positive cells are present in the subventricular layer
of the telencephalic cortex in the E14.5 brain, but no GFAP
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GFAP expression in neural precursor cells is dependent on the
activation of STAT3 [14–16]. Furthermore, we have shown
that the CpG dinucleotide within a particular STAT3 binding
element in the GFAP promoter is highly methylated in E11.5
neuroepithelial cells, post-mitotic neurons and cells outside the
nervous system, but is demethylated in cells where STAT3
induces the expression of GFAP [17]. GFAP is known as an
index of astrocyte maturation [13]. Our data on the S100b gene
promoter support the idea that DNA demethylation of as-
trocyte speciﬁc gene promoters in neural progenitors is a key
event during mid-gestation as part of a cell-intrinsic program
for astrogenesis. Thereafter, cell-external cues such as BMP2
may help neural progenitors to switch from neurogenesis to
astrogenesis and result in STAT3 activation signals promoting
maturation of astrocytes in the last stage of CNS development.
In this paper, we show that MeCP2 binds to the speciﬁc
methylated CpG site within the S100b gene promoter and
suggest that the binding of MeCP2 inactivates the gene in
E11.5 neuroepithelial cells. It has been reported that regulation
of the interaction between MeCP2 and methylated DNA is
critical for neurogenesis during Xenopus development and for
neuronal activity-dependent recent BDNF expression [30–32].
Thus, it is becoming increasingly apparent that MeCP2-bind-
ing to the methylated CpG site in a speciﬁc promoter plays a
key role in the development of CNS and in the establishment
of functional neural network. More studies are needed to fully
explain how methylation or demethylation of speciﬁc gene
promoters is regulated.
In conclusion, taken together with our previous report on
the GFAP gene promoter [17], methylation of cell type-speciﬁc
gene promoters may be a pivotal event in regulating lineage
speciﬁcation during brain development.
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